Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEd Study in Relapsed/Progressed Multiple Myeloma
NCT03155100Phase 2Completed
- Start
- Aug 2017
- Primary completion
- Aug 2023
- Modality
- Reversible Covalent Inhibitors, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib and elotuzumab in multiple myeloma (MM). Primary endpoint: Overall Response Rate at 3 years. Started Aug 2017; status: completed.
02
Drugs
carfilzomibelotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03155100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03155100.